10 March 2026
Monument Therapeutics announces first patient dosed in clinical trial of MT1988 in patients at clinical high risk for psychosis
Manchester, UK, March 10, 2026 - Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis. The study is being conducted...
23 February 2026
Biofortuna pioneers new robotic system for diagnostic tests
A North Wales biotechnology company has developed a new robotic dispensing system designed to improve the production of diagnostic testing devices used to detect conditions including cancer. Deeside-based Biofortuna secured £225,000 through the Welsh Government’s SMART Flexible...
11 February 2026
Proveca announces exclusive worldwide development and license agreement with Catalent for its Zydis® ODT technology for use with Glycopyrrolate
This press release is intended for investors only. 10th February 2026 - Proveca, a pharmaceutical company specialising in medicines for children, announced today that it has entered into an exclusive worldwide development and license agreement with Catalent, a leading global...
21 January 2026
QV Bioelectronics receives £4.5m boost for implantable brain cancer therapy
A Cheshire-based medtech business has secured £4.5m of investment and grant funding to revolutionise treatment for the most common type of primary brain cancer in adults. The investment round was led by PXN Ventures, which launched following the merger between Praetura Ventures...